Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31500792 | 0.76 | ALDH1A1 (0.38) | KMT2AMEN1ALDH1A1MAPTADH1A | |
| SCHEMBL2875858 | 0.72 | ATM (0.40) | KMT2AATMALDH1A1POLBTSHR | |
| SCHEMBL11209209 | 0.72 | TSHR (0.50) | KMT2AMEN1ATMALDH1A1TSHR | |
| SCHEMBL9816779 | 0.71 | ATM (0.54) | KMT2AMEN1ATMALDH1A1POLB | |
| SCHEMBL965411 | 0.71 | ATM (0.54) | KMT2AMEN1ATMALDH1A1POLB | |
| SCHEMBL965799 | 0.69 | ATM (0.51) | KMT2AMEN1ATMALDH1A1POLB | |
| SCHEMBL13657553 | 0.68 | ATM (0.37) | KMT2AATMALDH1A1POLBTSHR | |
| SCHEMBL968899 | 0.67 | L3MBTL1 (0.46) | KMT2AMEN1ALDH1A1TSHRRAB9A | |
| SCHEMBL39462 | 0.67 | ADRA2A (0.40) | KMT2AATMALDH1A1POLBTSHR | |
| SCHEMBL27576790 | 0.67 | TSHR (0.41) | KMT2AMEN1ATMALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119868249-A | Transdermal delivery formulation | 阿尔伯特爱因斯坦医学院 | 2025-04-25 | — | — | CN | disclosed |
| CN-119630394-A | Chelating agents for cancer treatment | 普雷高治疗有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-114761389-B | Phospholipid-FLAVAGLINE conjugates and methods for their use in targeted cancer therapy | 塞勒科塔生物科学公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-117940567-A | Antisense compounds that modulate the expression of WFDC2 | 克迈恩有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117337174-A | Transdermal pharmaceutical formulation comprising CBD or THC for the treatment of cancer | 长矛治疗股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-113151280-B | Application of small-molecule non-coding RNA and host gene in diagnosis and treatment of gastric cancer | 暨南大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-109071671-B | ERBB2 targeting antibodies | 意大利乔凡尼洛伦齐尼生物化学研究所股份公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-105886506-A | Antisense modulation of PTP1B expression | ISIS制药公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-103547588-B | Antisense modulation of PTP1B expression | ISIS制药公司 | 2016-06-29 | — | — | CN | disclosed |
| CN-103597074-A | Antisense modulation of fibroblast growth factor receptor 4 expression | ISIS PHARMACEUTICALS INC | 2014-02-19 | — | — | CN | disclosed |
| CN-103547588-A | Antisense modulation of PTP1B expression | ISIS PHARMACEUTICALS INC | 2014-01-29 | — | — | CN | disclosed |